Navigation Links
Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Date:9/27/2011

ROCKVILLE, Md., Sept. 27, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that Eva Feldman, MD, PhD, Principal Investigator of the Phase I safety trial of Neuralstem's human spinal cord stem cells (HSSC's) in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), presented primary and secondary endpoint data on the first 12 patients at the American Neurological Association's annual meeting (http://www.aneuroa.org/i4a/pages/index.cfm?pageID=3311). Dr. Feldman, an unpaid consultant to Neuralstem, is also Director of the A. Alfred Taubman Medical Research Institute, the Director of Research of the ALS Clinic at the University of Michigan Health System and the incoming American Neurological Association President.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"Eight out of ten living subjects in the trial showed lower extremity function scores that remained the same or improved after treatment," commented. Dr. Feldman. "Two out of ten showed continued decline of lower extremity function. The sample size and follow-up time are too limited to draw any conclusions, but we are encouraged by the safety profile of our approach."

"This trial is designed to assess the safety of intraspinal transplantation in ALS. It is not  an efficacy trial," said Karl Johe, PhD, Neuralstem Chairman and Chief Scientific Officer. "All assessments have proven the procedure to be safe. We have had no serious adverse events related to either the surgical procedure or our cells in the first 12 subjects.  This is a very important first step to delivering the promise of our neural stem cell therapeutics."

"We are encouraged by these data," said Richard Garr, Neuralstem CEO and President. "Our next step is to continue the trial, testing the safety of our intraspinal inj
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
2. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
3. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
4. /C O R R E C T I O N -- Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee/
5. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
6. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
7. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
8. Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note
9. International Merchant Advisors Reaches Agreement in Principal to Acquire First Medical Marijuana Clinic Operations
10. NeoStem Announces Warrant Exercise by Principal Shareholder
11. Pascal Metrics Welcomes Jim Conway to Leadership Team as Principal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Aug. 18, 2014 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p01597713/Bioseparation-Systems-for-Global-Biopharmaceutical-Markets.html ... three types: chromatography, membranes/filters and centrifuges. The ... and fueling growth of the global bioseparations ...
(Date:8/18/2014)... YORK , Aug. 18, 2014 ... is available in its catalogue: ... 2020 http://www.reportlinker.com/p02280986/Russia-Bariatric-Surgery-Devices-Market-Outlook-to-2020.html ... 2020 Summary GlobalData,s ... to 2020", provides key market data on the ...
(Date:8/18/2014)... Nev., Aug. 18, 2014 PDL BioPharma, Inc. (PDL) ... for the second quarter and six months ended June 30, ... quarter of 2014 increased approximately 10 percent to $162.8 ... 2013. Revenues for the second quarter of 2014 include ... al. patents, net royalty payments from Depomed, the change ...
Breaking Medicine Technology:Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12Russia Bariatric Surgery Devices Market Outlook to 2020 2Russia Bariatric Surgery Devices Market Outlook to 2020 3Russia Bariatric Surgery Devices Market Outlook to 2020 4Russia Bariatric Surgery Devices Market Outlook to 2020 5PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 2PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 3PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 4PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 5PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 6PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 7PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 8PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 9PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 10PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 11
... 23 Kensey Nash Corporation (Nasdaq: KNSY ), ... a wide range of medical procedures, today reported the results ... 2010.   Fourth Quarter Snapshot and Recent ... the quarter, exceeding the high end of the Company,s previous ...
... 23 Uroplasty, Inc. (Nasdaq: UPI ... and markets innovative proprietary products to treat voiding ... and Palmetto GBA, South Carolina, both regional Medicare ... (PTNS) using the Urgent® PC Neuromodulation System for ...
Cached Medicine Technology:Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 2Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 3Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 4Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 5Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 6Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 7Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 8Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 9Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 10Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 11Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 12Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 13Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results 14Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System 2Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System 3
(Date:8/19/2014)... Merrick, NY (PRWEB) August 19, 2014 In honor ... helping you care for your old furry friend by offering tips ... to rely on their owners more. Because of this, dog owners ... for them. , As dogs age, their needs change. They will ... outside as much as they used to. Because of this, pet ...
(Date:8/19/2014)... Following the completion of a $16 million rooms ... is proud to debut the highly anticipated final phase of ... revamp of all public spaces to match the fresh look ... all-new dining experience at 1823 Kitchen and Bar and an ... introduction of 1823 Kitchen and Bar, Grand Hyatt Tampa Bay ...
(Date:8/19/2014)... cannot smoke during their stay and could use this time ... stay smoke-free after returning home. Now a study published ... a program that increased the proportion of hospitalized smokers who ... The system used interactive voice response technology automated ... three months after smokers left the hospital. , ...
(Date:8/19/2014)... 2014 Warfarin, the longtime standard treatment for ... in the anticoagulant drug marketplace including dabigatran, rivaroxaban, ... adoption of these novel oral anticoagulants (NOACs) into ... of all new anticoagulant prescriptions yet this represents ... published in The American Journal of Medicine ...
(Date:8/19/2014)... York, New York (PRWEB) August 19, 2014 ... U.S. courts, Bernstein Liebhard LLP notes the publication of ... antipsychotic medications may increase the risk of acute kidney ... by The Ottawa Citizen, the study was conducted by ... Ont., and the Institute for Clinical Evaluative Sciences, and ...
Breaking Medicine News(10 mins):Health News:The Puppy Store Helps Pet Owners Care for Aging Dogs 2Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2Health News:Extended support helps patients stay smoke-free after hospital discharge 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 2Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 4
... Grubb & Ellis Healthcare,REIT, Inc. today announced the acquisition ... 5550 South East St., Epler Parke Building B is ... square feet of gross leaseable area., Built in ... offers 196 parking spaces and is accessible by Interstates ...
... Iomai Corporation,(Nasdaq: IOMI ) today announced, ... audit report included in the Company,s Annual,Report on ... Commission on,March 27, 2008 for the fiscal year ... This disclosure is required under NASDAQ,marketplace rules and ...
... ULURU Inc. (Amex:,ULU) today announced that it has scheduled ... results and provide a general business update,on Tuesday, April ... participate in the conference call, please dial (800) 357-0498 ... to ten,minutes prior to the initiation of the teleconference. ...
... Conn., March 28 Darwin,Professional Underwriters, Inc. ... the,resignation of Paul F. Romano, who served ... Thursday, March 27th. Mr. Romano has become,associated ... the,Hartford area., (Logo: http://www.newscom.com/cgi-bin/prnh/20060829/NETU014LOGO ...
... suffers collateral damage from blood sugar disease , , FRIDAY, ... cause of heart disease, stroke, blindness, kidney failure and ... quicker than they normally do with age, a new ... in lung function as they grow older, research published ...
... With the full House and,Senate poised to ... Relief,(PEPFAR) reauthorization bill, a five-year, $50 billion initiative ... address,the critical HIV prevention shortfalls in the bill., ... to anti-retroviral drugs,(ARVs) since PEPFAR was enacted in ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Acquires Epler Parke Building B in Indianapolis 2Health News:Grubb & Ellis Healthcare REIT Acquires Epler Parke Building B in Indianapolis 3Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update 2Health News:Darwin Announces Departure of Senior Vice President 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Will Congress Do More for HIV Prevention? 2Health News:Will Congress Do More for HIV Prevention? 3Health News:Will Congress Do More for HIV Prevention? 4
... The Brasseler USA™ Battery Packs contain ... age have a great impact upon battery ... is necessary. Any deviation from these recommendations ... are sensitive to heat. Any exposure of ...
Pneumatic High-speed Drill, Throttleless, 90k Rpm, Microaire Connector....
Pneumatic foot surgical oscillating saw, 24k cpm, available with various hose connector styles....
... Motor Module, without throttle (MicroAire hose connector). ... attachments., ,1050-100 model requires 10ft. ... MicroAire connector. Also requires 9100-000 Foot Control ... hose 9013-000, or existing hose with Linvatec/Hall ...
Medicine Products: